Pharmaxis Ltd. operates as a specialty pharmaceutical company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. It operates through the following segments: Bronchitol and Aridol Business and New Drug Development. The Bronchitol and Aridol Business segment covers the ongoing clinical development, manufacture, and sale of the Bronchitol and Aridol globally. The New Drug Development segment encompasses the drug discovery and early stage clinical development of the new drug candidates. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
|Market Price at 19-01-2018||$0.27|
|Price to Earnings Ratio||-4.31|
|Market Capitalisation||$86.16 (million)|
|Return on Equity (ROE)||-524.72%|